VALERIO THERAPEUTICS Aktie

 

Shareholder approval and settlement and delivery of the capital increases related to the Acquisition The Acquisition marks a major milestone in Valerio's strategy to build a leading integrated platform to support progress toward the clinic €40.25 million financing secured in August 2026 supports Etherna's integration and the next development milestones VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News Valerio Therapeutics (FR0010095596 - ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), today announces the completion of the acquisition of 100% of the share capital and voting rights of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"). Further to the closing of the cash consideration of the Acquisition which occurred in August1, the Company has now proceeded to the settlement of the share consideration, marking the last step of the Acquisition. The Acquisition marks a major milest...

Operational launch of InVimmune, a subsidiary dedicated to differentiated approaches to in vivo cell therapy, with a first indication announced in oncology. Appointment of Gilles Besin as Chief Executive Officer, effective July 2026. Signing of a binding term sheet with Abivax with a view to an exclusive global collaboration. Achievement of a major strategic milestone with the acquisition of Etherna Immunotherapies NV; the transaction is expected to be finalised on 8 October 2026. Cash and cash equivalents totaling €656,000 as at 30 June 2026. As of the date of the half-year financier report, the cash position covers 12 months. VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a pioneering biotechnology company in the field of next-generation precision therapies (“Valerio”, or the “Company”), provides an update on its operations and presents its financial results for the half-year ended 30 June 2026. “The first half of 2026 marked a decisive mile...

Definitive share purchase agreement signed for the acquisition of 100% of Etherna Immunotherapies NV ("Etherna"), and the related contribution agreement, based on an enterprise value of €30 million, to be settled through a combination of a cash consideration and a share consideration (the "Contributions") €40.25 million PIPE financing successfully priced with support from new and existing investors, to finance the cash consideration of the Acquisition and support the development of the combined company Shareholder approval of the Contributions, at an extraordinary general meeting to be convened for that purpose, with approval already secured through irrevocable voting undertakings from existing shareholders representing more than 70% of the voting rights of the Company The Acquisition marks a major milestone in Valerio's strategy to build a leading platform in the development of next-generation precision-guided RNA therapeutics VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: ...

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), provides an update on the contemplated acquisition of 100% of the share capital of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"). On July 1, 2026, Valerio announced the submission of a binding offer for the Acquisition on the basis of an enterprise value of EUR 30 million. In connection with the binding offer, Valerio and Etherna had initially agreed to a six-week exclusivity period to finalise the definitive transaction documentation. Since that announcement, the parties have made substantial progress towards the contemplated Acquisition, including the receipt of the required foreign direct investment clearance. Valerio has agreed to continue the constructive discussions with Etherna to work towards finalising the definitive agreements, with a...

The proposed acquisition represents a major step in Valerio's strategy to become a leading developer of next-generation targeted RNA medicines targeting cells beyond the liver, addressing diseases with high unmet medical needs The acquisition aims to create the only player combining active sdAb targeting and passive LNP delivery within a fully integrated RNA medicines platform, accelerating the development of therapeutics and supporting a growing proprietary pipeline The news follows the recent appointment of seasoned biotech leader Gilles Besin as Chief Executive Officer to lead Valerio's next phase of innovation in precision targeted therapeutics, bringing deep expertise in RNA medicines, targeted delivery and in vivo cell therapy Supported by leading life sciences investors, with key Etherna shareholders becoming Valerio shareholders as part of the transaction, reflecting confidence in the strategic vision and value creation potential of the combined entities 6-week exclusivity period to finalize tra...

Seasoned biotech leader with deep expertise in RNA medicines, targeted delivery, and in vivo cell therapy joins to drive Valerio's next phase of innovation in precision targeted therapeutics Gilles Besin, Ph.D., appointed Chief Executive Officer effective 1 July 2026, as part of a planned governance transition, bringing a proven track record of building and scaling biotechnology companies through major value-creating milestones directly aligned with the Company's strategic roadmap Approval by the shareholders' general meeting of [all] resolutions recommended by the Board of Directors VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a clinical-stage biotechnology company pioneering next-generation precision-guided therapeutics (the "Company"), today announces the appointment of Gilles Besin, Ph.D. as Chief Executive Officer by the Board of Directors, effective 1 July 2026, as well as the results of the votes at its shareholders' general meeti...

PARIS--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (“Valerio Therapeutics” or the “Company”) (Euronext Growth Paris: ALVIO) announces the appointment of Professor Eric Vivier as an Observer to its Board of Directors. His nomination as a Director will be submitted to shareholders at the Company's next general meeting. Professor Eric Vivier works within Aix Marseille University and Assistance Publique-Hôpitaux de Marseille (AP-HM) and is also a professor at École Polytechnique (X). He leads an immunology research group at the Centre d'Immunology de Marseille-Luminy. Internationally recognized for his work, he is a laureate of the European Research Council (ERC) and the recipient of numerous national and international research awards. His major scientific contributions have earned him membership in the French National Academy of Medicine and a place among the Highly Cited Researchers, a ranking of the world's most influential scientists. Through his research, hospital commitment, and ...